In contrast, the presence of TP53 co-mutation with STK11—even in the context of KRAS mutation—confers a better prognosis, suggesting that the interplay between these tumor suppressors and oncogenes is complex and context-dependent [55]. The gene discussed is KRAS; the disease is neoplasm.